Table 3.
Means of instruments at baseline and follow-up, overall, and by surgery type.
| Radical trachelectomy |
Radical hysterectomy |
Overall |
Wilcoxon Rank-Sum |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total n | Mean | (SE) | Total n | Mean | (SE) | Total n | Mean | (SE) | P value | ||
| Concern cancer will come back | |||||||||||
| (O: not at all to 10 very concerned) | Initial assessment | 43 | 5.66* | (0.39) | 28 | 7.27* | (0.56) | 71 | 6.3 | (0.34) | 0.008* |
| 3-month follow-up | 28 | 5.91 | (0.45) | 14 | 4.96 | (0.5) | 42 | 5.6 | (0.34) | 0.147 | |
| 6-month follow-up | 31 | 5.6 | (0.31) | 14 | 5.36 | (0.78) | 45 | 5.52 | (0.32) | 0.682 | |
| 12-month follow-up | 29 | 5.16 | (0.35) | 13 | 5.08 | (0.75) | 42 | 5.13 | (0.33) | 0.923 | |
| 18-month follow-up | 27 | 4.61 | (0.41) | 11 | 5.27 | (0.69) | 38 | 4.80 | (0.35) | 0.376 | |
| 24-month follow-up | 26 | 4.21 | (0.42) | 14 | 4.86 | (0.81) | 40 | 4.44 | (0.39) | 0.529 | |
| CES-D total score | |||||||||||
| Range = 0 to 60 | Initial assessment | 42 | 17.48 | (1.83) | 27 | 20.3 | (2.61) | 69 | 18.58 | (1.51) | 0.382 |
| Clinical cut-off: 16+ depression | 3-month follow-up | 28 | 13.4 | (1.69) | 15 | 14.13 | (3.19) | 43 | 13.66 | (1.54) | 0.990 |
| 6-month follow-up | 30 | 16.77 | (2.55) | 14 | 8.91 | (2.28) | 44 | 14.27 | (1.95) | 0.082 | |
| 12-month follow-up | 29 | 10.59 | (2.17) | 13 | 10.08 | (2.75) | 42 | 10.43 | (1.7) | 0.881 | |
| 18-month follow-up | 27 | 11.96 | (0.41) | 11 | 8.36 | (1.50) | 38 | 10.92 | (1.80) | 0.922 | |
| 24-month follow-up | 26 | 10.04 | (2.21) | 14 | 11.14 | (2.91) | 40 | 10.43 | 1.74 | 0.579 | |
| FSFI total score | |||||||||||
| Range = 0 to 95 | Initial assessment | 43 | 17.43 | (1.79) | 26 | 15.72 | (2.3) | 69 | 16.79 | (1.4) | 0.696 |
| Clinical cut-off: <26.55 sexual dysfunction | 3-month follow-up | 28 | 17.29 | (1.91) | 15 | 20.58 | (2.45) | 43 | 18.43 | (1.51) | 0.268 |
| 6-month follow-up | 31 | 20.8 | (1.82) | 14 | 23.66 | (2.78) | 45 | 21.69 | (1.52) | 0.309 | |
| 12-month follow-up | 29 | 23.04 | (1.79) | 13 | 25.44 | (2.55) | 42 | 23.78 | (1.46) | 0.496 | |
| 18-month follow-up | 25 | 23.14 | (2.16) | 10 | 25.01 | (2.70) | 35 | 23.68 | (1.71) | 0.971 | |
| 24-month follow-up | 26 | 21.97 | (2.27) | 14 | 22.63 | (2.91) | 40 | 22.20 | (1.77) | 0.921 | |
| IES total score | |||||||||||
| Clinical cut-offs: 0-8 subclinical | Initial assessment | 42 | 35.39 | (2.4) | 26 | 33.63 | (3.54) | 68 | 34.72 | (1.99) | 0.760 |
| 9-25 Mild | 3-month follow-up | 27 | 25.89 | (3.24) | 15 | 23.4 | (4.82) | 42 | 25 | (2.67) | 0.780 |
| 26-43 Moderate | 6-month follow-up | 31 | 27.42 | (3.29) | 14 | 26.14 | (5.74) | 45 | 27.03 | (2.85) | 0.750 |
| 44+ Severe | 12-month follow-up | 29 | 17.07 | (2.79) | 13 | 20.48 | (3.11) | 42 | 18.13 | (2.15) | 0.240 |
| Range = 0 to 75 | 18-month follow-up | 27 | 18.93 | (3.25) | 11 | 14.55 | (2.21) | 38 | 17.66 | (2.40) | 0.772 |
| 24-month follow-up | 26 | 13.65 | (2.75) | 14 | 15.46 | (3.05) | 40 | 14.29 | (2.06) | 0.379 | |
| FACT Phys well-being | |||||||||||
| Range= 0 to 28 | Initial assessment | 42 | 24.68 | (0.59) | 27 | 22.4 | (1.14) | 69 | 23.79 | (0.58) | 0.068 |
| 3-month follow-up | 28 | 24.35 | (0.68) | 15 | 21.86 | (1.68) | 43 | 23.48 | (0.75) | 0.170 | |
| 6-month follow-up | 31 | 23.01 | (0.94) | 13 | 24.31 | (1.43) | 44 | 23.39 | (0.78) | 0.218 | |
| 12-month follow-up | 29 | 25.76 | (0.6) | 13 | 25.15 | (0.93) | 42 | 25.57 | (0.5) | 0.369 | |
| 18-month follow-up | 27 | 24.57 | (0.84) | 11 | 26.36 | (0.45) | 38 | 25.09 | (0.62) | 0.442 | |
| 24-month follow-up | 26 | 26.12 | (0.38) | 14 | 26.13 | (0.58) | 40 | 26.12 | (0.31) | 0.965 | |
| FACT Soc/family well-being | |||||||||||
| Range= 0 to 28 | Initial assessment | 42 | 23.17* | (0.77) | 28 | 20.33* | (0.99) | 70 | 22.04 | (0.63) | 0.017* |
| 3-month follow-up | 28 | 20.92 | (1.26) | 15 | 22.86 | (0.99) | 43 | 21.59 | (0.89) | 0.583 | |
| 6-month follow-up | 31 | 20.58 | (1.18) | 13 | 23.15 | (1.04) | 44 | 21.34 | (0.9) | 0.394 | |
| 12-month follow-up | 29 | 22.11 | (1.08) | 13 | 22.69 | (1.04) | 42 | 22.29 | (0.81) | 0.978 | |
| 18-month follow-up | 27 | 21.27 | (1.25) | 11 | 23.55 | (1.06) | 38 | 21.93 | (0.95) | 0.560 | |
| 24-month follow-up | 26 | 21.77 | (1.08) | 14 | 22.17 | (1.34) | 40 | 21.91 | (0.84) | 0.955 | |
| FACT emotional well-being | |||||||||||
| Range= 0 to 24 | Initial assessment | 43 | 13.79 | (0.64) | 28 | 12.31 | (1.11) | 71 | 13.2 | (0.59) | 0.197 |
| 3-month follow-up | 28 | 17.61 | (0.56) | 15 | 18.95 | (0.86) | 43 | 18.07 | (0.48) | 0.143 | |
| 6-month follow-up | 31 | 17.19 | (0.71) | 14 | 18.64 | (1.47) | 45 | 17.64 | (0.67) | 0.157 | |
| 12-month follow-up | 29 | 18.9 | (0.76) | 13 | 16.98 | (1.49) | 42 | 18.3 | (0.7) | 0.229 | |
| 18-month follow-up | 27 | 18.96 | (0.78) | 11 | 18.27 | (0.99) | 38 | 18.76 | (0.62) | 0.383 | |
| 24-month follow-up | 26 | 19.42 | (0.55) | 14 | 19.57 | (1.01) | 40 | 19.48 | (0.49) | 0.775 | |
| FACT functional well-being | |||||||||||
| Range= 0 to 28 | Initial assessment | 43 | 19.48 | (0.86) | 28 | 17.07 | (1.3) | 71 | 18.53 | (0.74) | 0.166 |
| 3-month follow-up | 28 | 21.99 | (0.9) | 15 | 18.42 | (1.9) | 43 | 20.74 | (0.91) | 0.105 | |
| 6-month follow-up | 31 | 21.32 | (1.05) | 14 | 22.5 | (1.33) | 45 | 21.69 | (0.83) | 0.579 | |
| 12-month follow-up | 29 | 23.52 | (0.94) | 13 | 21.85 | (1.4) | 42 | 23 | (0.78) | 0.170 | |
| 18-month follow-up | 27 | 22.81 | (1.11) | 11 | 23.91 | (1.11) | 38 | 23.13 | (0.85) | 0.820 | |
| 24-month follow-up | 26 | 23.92 | (0.96) | 14 | 21.86 | (1.50) | 40 | 23.20 | (0.82) | 0.257 | |
| FACT-G total score | |||||||||||
| Range= 0 to 108 | Initial assessment | 42 | 80.92 | (2.02) | 27 | 72.32 | (3.63) | 69 | 77.55 | (1.93) | 0.063 |
| 3-month follow-up | 28 | 84.85 | (1.96) | 15 | 82.09 | (4.45) | 43 | 83.89 | (1.99) | 0.889 | |
| 6-month follow-up | 31 | 82.1 | (3.16) | 13 | 89.15 | (4.08) | 44 | 84.19 | (2.55) | 0.316 | |
| 12-month follow-up | 29 | 90.28 | (2.7) | 13 | 86.68 | (4.01) | 42 | 89.17 | (2.23) | 0.294 | |
| 18-month follow-up | 27 | 87.62 | (3.29) | 11 | 92.09 | (2.57) | 38 | 88.91 | (2.45) | 0.936 | |
| 24-month follow-up | 26 | 91.23 | (2.46) | 14 | 89.73 | (3.70) | 40 | 90.70 | (2.03) | 0.809 | |
*
Indicates that the means for the two surgery groups were significantly different, P<0.05, before correcting for multiple comparisons using the false discovery rate method. No test remained significant after correcting for multiple comparisons.